For example, the TG01 peptide cocktail, which incorporates multiple KRAS mutant peptides, has been combined with granulocyte‐macrophage colony‐stimulating factor to enhance antigen presentation and immune activation in pancreatic cancer (NCT02261714).[58] However, while peptide‐based vaccines offer a potential means of targeting KRAS‐driven malignancies, mRNA‐based platforms provide a more versatile and scalable approach, capable of rapid adaptation to different tumor neoantigens. Here, KRAS is linked to neoplasm.